ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) REPORT

HELP PEOPLE WITH CANCER LIVE LONGER AND BETTER

3DMed
思路迪

3DMed
思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)
Stock Code: 1244

2023
ENVIRONMENTAL SOCIAL AND GOVERNANCE REPORT

3DMed
思路迪

About the Report

Reporting Period

This Environmental, Social and Governance (ESG) Report (hereinafter referred as the "Report") covers the period from January 1 to December 31, 2023, with some content moderately extended forward and backward. The reporting period covered in the Report is consistent with that of our annual report.

Entity Scope

The entity scope covered in the Report is consistent with that of our annual report, including 3D Medicines Inc. and its subsidiaries.

Basis of Preparation

The Report is prepared in accordance with the provisions of Appendix 27 Environmental, Social, and Governance Reporting Guide (hereinafter referred to as the "Guide") to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and a summary of its major amendments. The Report has been reviewed and approved by the Company's Board of Directors (the "Board"). Readers can refer to the last chapter of the Report - "Appendix: Index to the Environmental, Social and Governance Reporting Guide of The Stock Exchange of Hong Kong Limited" for quick reference.

Data Source

All the qualitative and quantitative information used in the Report originates from public information, internal documents, and relevant statistical data of 3D Medicines.

Preparation Principle

The Report considers the importance, quantification, balance, and consistency of specific indicators related to performance disclosure on major ESG topics. Importance: Identify and rank important topics for stakeholders through policy and standard analysis and communication with stakeholders; Quantification: All key performance indicators ("KPIs") disclosed can be measured; Balance: Objectively present the Company's work in ESG in the Report; Consistency: The ESG report in this year adopts the same data disclosure method as previous years and compares data from different years, and lists changes in statistical methods and key performance indicators.

Reference Help

For ease of expression and reading, 3D Medicines Inc. is also referred to as "the Company" or "we" in the Report. Unless otherwise defined, the terms and definitions used in the Report have the same meaning as those used in the 2023 annual report.

Release Form

The electronic version of the Report is available at the HKEX website (www.hkex.com.hk) and the official website of 3D Medicines Inc. (https://www.3d-medicines.com/).

CONTENTS

Message from the Chairman

In 2023, with the increasing attention and further development of ESG concepts, 3D Medicines Inc. has also integrated it as an important work into daily operations. We always adhere to the concept of sustainable development, with the vision of "helping people with cancer live longer and better", to the principle of benefiting people and society, and to the construction of a first-class innovative pharmaceutical enterprise that is friendly to environment and society.

We are committed to building a comprehensive ESG management system. ESG work takes the Board of Directors as the highest decision-making body, with the Board Office responsible for strategy implementation and management. And an ESG work team is established to be responsible for the implementation and deepening of specific matters of ESG management.

Innovation and R&D have always been the driving force for the sustainable development of the company. We focus on managing cancer as a chronic disease, hoping to provide patients with more effective and convenient cancer treatment drugs and treatment options as early as possible. Based on the true clinical orientation of patients, we continuously discover and promote the R&D of innovative drugs to meet more clinical needs. At the same time, we improve drug accessibility and reduce the burden on patients by obtaining recommendation for clinical treatment guidelines, joining local policies of benefiting people and providing charitable contribution and multiple sales channels.

Being responsible for patients is a common responsibility of pharmaceutical companies, so we have established a complete quality management system to systematically supervise and manage our R&D, production and the seals of upstream and downstream enterprises and to control production risks. Meanwhile, we timely understand patient demands through various platforms and third-party suppliers, provide medication guidance for patients, and ensure that patients use our drugs correctly and safely.

Win-win cooperation is an important development concept for the company. We have collaborated with a number of leading innovative pharmaceutical companies at home and abroad. We are not only committed to introducing excellent overseas innovative drugs into China, but also continuously cooperate with excellent local enterprises to develop advantageous innovative drugs. We hope to promote Chinese innovative drugs globally in the future.

Employees are the cornerstone of a company's creativity and development. We continue to put people first, establish a sound and fair mechanism for personnel employment, selection, and development, provide employees with a comfortable and healthy working environment and regular physical examinations and commercial medical insurance, and ensure the health and safety of employees.

We continue to operate with integrity and continuously strengthen risk and internal control management. We carry out anti-corruption work internally and set up a special supervision and management department. At the same time, we gradually optimize our procurement system, carry out transparent procurement management, implement three-party price comparison, and advocate market-oriented procurement and cooperation.

We establish a green environmental management system to reduce the impact and harm to the environment while conducting experiment and production. We use advanced sewage treatment systems and exhaust systems to ensure the safe discharge of harmful substances. We actively respond to climate change, identify and evaluate the opportunities and challenges that climate change may bring, minimize energy use and consumption as much as possible, so as to establish an environmentally friendly society.

In the future, we will continue to take building an environmentally and socially friendly sustainable development enterprise as our overall ESG strategic goal, actively assume more social responsibilities, increase our social value, contribute to society in return, and benefit people.

Company Profile

3D Medicines Inc. is a commercial-stage biopharmaceutical company focusing on managing cancer as a chronic disease. With the vision of "helping people with cancer live longer and better", we develop a new generation of anti-tumor drugs. The Company's product pipeline includes 12 innovative drugs with clinical value, of which 8 have entered the clinical development or commercialization stage, including 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1), a novel subcutaneous PD-L1 domain antibody, which has been approved for sale by the National Medical Products Administration. Relying on the Company's own mRNA R&D platform and oncogenomics big data AI analysis platform, we develop a series of mRNA products. The Company's independently developed multi-target kinase inhibitor 3D011 has also entered the clinical development stage, with preclinical products including the internationally leading CD3xPD-L1 bispecific antibody. The Company has established capabilities in drug discovery, preclinical research, clinical development, market application, and commercialization. With patient-centered principle, the Company is committed to developing new drugs with differentiated clinical values.



Vision

Help people with cancer live longer and better

Positioning

Leader in helping chronic tumor patients

Mission

Prolong the life span of cancer patients and improve the quality of their life

R&D platform

The Company has a professional R&D platform in the field of managing tumor as a chronic disease, on which we can carry out a series of R&D activities including drug activity screening, drug cell function study, drug biochemical study and biomolecule detection.

The Company's R&D platform has strong molecular screening and design capabilities to increase the success rate of molecules from preclinical study to market, and support the R&D of pipeline assets built around key pathways and targets.

We have established mature R&D centers in Shanghai and Beijing respectively, including large and small molecular platforms, cell line screening platforms, and compound screening platforms.

We has established our own mRNA R&D platform and oncogenome big data AI analysis platform, and developed a series of mRNA products.



Product pipeline

The Company has established a diversified pipeline layout that includes 12 products and candidate drugs. Among them, 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) was approved and commercialized in China in November 2021. The Company also has bispecific antibodies in the preclinical stage and mRNA candidates in the Cellular and Gene Therapy region.

Drug Development Pipeline Overview

Candidate	Target / Mechanism	Indications/Study Population	Rights
恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1)	PD-L1	MSI-H/dMMR Advanced Cancer (Mono, 2L+)	Global
		Advanced BTC (Combo with chemo vs. chemo, 1L)	
		NSCLC (Adjuvant/Neo-adjuvant therapy, 1L)	
		G/GEJ Advanced Cancer (Combo with chemo, 1L)	
		TMB-H Advanced Cancer (Mono, 2L+)	
		EC (Mono and combo with lenvatinib, 2L+)	
		HCC, CRC, NSCLC (Combo with BD0801)	
		Microsatellite Stable CRC (combo with cetuximab+/-Fruquintinib, standard treatment failure)	
		dMMR Advanced Solid Tumor (Mono，2L+)	
3D189	WT1 Cancer Vaccine	Multiple indications	Greater China
		AML	
3D229	GAS6/AXL	Healthy Volunteers	Greater China
3D1001	COX-2	Post-surgical Dental Pain/Cancer Pain	Greater China
3D1002	EP-4	Cancer Pain/Osteoarthritis	Greater China
3D185	FGFR1/2/3	Locally Advanced or Metastatic Solid Tumors	Global
3D011	TKI prodrug	Advanced Malignant Solid Tumors	Global
3D197	CD47	Multiple indications	Greater China
3D057	CD3+PD-L1	Multiple indications	Greater China priority transfer rights
3D124	mRNA Cancer Vaccine	Multiple indications	Global
3D062	KRAS	Multiple indications	Global
3D059	WT1 Cancer Vaccine	Multiple indications	Greater China



◉ Pivotal Trial

Major Events in 2023

January

3D185 - certified by FDA as an orphan drug for the treatment of gastric cancer

On January 13, 2023, the candidate drug 3D185 under study was certified by the US Food and Drug Administration (FDA) as an orphan drug for the treatment of gastric cancer and gastroesophageal junction cancer. This was the second orphan drug certification granted to 3D185.

March

The Phase II clinical study of the combination of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) and BD0801 (treated with or without chemotherapy) for patients with advanced solid tumors completed patient enrollment.

The Company was included in the list of stocks under Shanghai-Hong Kong Stock Connect, becoming effective on March 13, 2023. On February 23, 2023, the Company was included by Hang Seng Index Services Limited in the Hang Seng Composite Index as a constituent stock, becoming effective on March 13, 2023.

April

The Company and INNOLAKE BIOPHARM (Hangzhou) Co., Ltd. continued to deepen their strategic partnership on the ILB-2109 project, with a focus on clinical development, drug strategy, and translational medicine.

Recommendation of 恩維達® (Envafo limab, Subcutaneously-Injectable PD-L1) in Chinese Clinical Authoritative Guidelines, Patients with MSI-H/dMMR advanced/recurrent gynecological tumors who have failed prior treatments in the Guidelines for Clinical Application of Gynecological Tumor Immune Checkpoint Inhibitors (Version 2023).

May

In May 2023, as the Company met the market value/income test requirements under Article 8.05(3) of the Listing Rules, the mark "B" was removed from the share name and share abbreviation of the Company following the non-application of Articles 18A.09-18A.11 of the Listing Rules.

June

The 2023 annual meeting of the American Society of Clinical Oncology (ASCO) was held in Chicago from June 2-6 Eastern Time. The two studies on 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1), an innovative drug under 3D Medicines, were announced at this annual meeting. Including:

- ASCO annual meeting (KN035 gastric cancer): New progress in multi-site Phase II clinical trial of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) combined with SOX in first-line treatment of advanced gastric cancer;
- ASCO annual meeting (KN035 sarcoma): Critical clinical study of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) in the treatment of advanced soft tissue sarcoma.

July

In July 2023, the Company raised approximately HKD 226.8 million through the placement of new shares to further strengthen our financial situation and accelerate our operations and the development of multiple clinical projects.

On July 18, 2023, the holder (MAH) of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) product passed the routine quality supervision and inspection of Sichuan Medical Products Administration with zero defects, which was also the first time that the Company had responded to the quality supervision and inspection of Sichuan Medical Products Administration after obtaining the drug production license (Class B).

Recommendation of 恩維達® (Envafo limab, Subcutaneously-Injectable PD-L1) in Chinese Clinical Authoritative Guidelines, Patients population with MSI-H/dMMR advanced/recurrent endometrial cancer in the Chinese Medical Association Clinical Guidelines for Gynecologic Oncology (Version 7. 2023).

August

KN035 CN017（PH3）IND

On August 23, 2023, the Company obtained a randomized, placebo-controlled, double-blind, multi-site Phase III clinical trial license from the National Medical Products Administration (Trial No. KN035 CN-017) for the neoadjuvant/adjuvant treatment of patients with resectable Phase III non-small cell lung cancer using the combination of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) and platinum-containing chemotherapy under the comparison with the combination of placebo and platinum-containing drug. The trial was submitted in June of the same year, with the aim of comparing the safety and efficacy of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1).

- **Specialized, refined, differentiated, and innovative SME**

  On August 23, 2023, 3D Medicines (Shanghai) Co., Ltd. was recognized as the second batch of "Specialized, Refined, Differentiated, and Innovative" SMEs in Shanghai for the year 2023, with a validity period of three years.

- **Cooperative development of mRNA therapeutic tumor vaccine**

  On August 26, 2023, the Company reached a cooperative development agreement with CanSino to work together on the next generation of mRNA tumor vaccines to provide more accurate treatment options for cancer patients.

September

The Phase I clinical study on the safety and immunogenicity of 3D189 in Chinese patients with hematological tumors completed patient enrollment. This was a multi-site, open, single-arm Phase I study aimed at evaluating the safety and immunogenicity of the 3D189 WT1 polypeptide vaccine in acute leukemia (AL) patients who were WT1 positive and had completely remitted after completing at least first-line standard treatment, and in patients with multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), or high-risk myelodysplastic syndrome (MDS) who had completely remitted or partially remitted .

October

On October 16, 3D Medicines (Sichuan) Co., Ltd., a subsidiary of the Company, was recognized as a "National High-Tech Enterprise".

KN035-US-004(Ph3) IND

On October 30, 2023, the Phase III clinical study (KN035-US-004) on the first-line treatment of patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer using the combination of Envafolimab® and Lenvatinib under the comparison with the carboplatin-paclitaxel chemotherapy was approved by the US Food and Drug Administration (FDA) for an investigational new drug clinical trial (IND).

恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) was selected to participate in the ESMO (European Society for Medical Oncology) annual meeting held in Madrid, Spain on October 20-24, 2023, which was one of the most influential cancer meetings in the world.

On October 11, 2023, the US National Comprehensive Cancer Network (NCCN) released the Chinese version of the 2023 NCCN Clinical Practice Guidelines in Cervical Cancer (1st Edition) and the Chinese version of the 2023 NCCN Clinical Practice Guidelines in Cervix Tumor (2nd Edition). Subcutaneous injection 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) was included in the two NCCN guidelines due to its excellent efficacy and safety, and was recommended as a second-line treatment of microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) advanced cervical or endometrial cancer.

November

On November 7, the US National Comprehensive Cancer Network (NCCN) released the Chinese version of the 2023 NCCN Clinical Practice Guidelines in Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer) (2nd Edition). Subcutaneous injection 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) was included in the NCCN guidelines due to its excellent efficacy and safety, and was recommended as a therapeutic drug for microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) ovarian cancer/fallopian tube cancer/primary peritoneal cancer.

To date, 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) has been included in three NCCN clinical guidelines, including:
1. 2023 NCCN Clinical Practice Guidelines in Cervical Cancer (2st Edition) (Chinese version)
2. 2023 NCCN Clinical Practice Guidelines in Cervix Tumor (2nd Edition) (Chinese version)
3. 2023 NCCN Clinical Practice Guidelines in Ovarian Cancer Including Carcinoma Tubae and Primary Peritoneal Carcinoma (2nd Edition) (Chinese version)

On November 24, 2023, the first-line treatment of mismatch repair proficiency (pMMR) advanced or recurrent endometrial cancer using the combination of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) and Lenvatinib under the comparison with the carboplatin-paclitaxel chemotherapy was recognized as a breakthrough therapy.

December

On December 14, the randomized, placebo-controlled, double-blind, multi-site Phase III clinical study (KN035-CN-017) on the neoadjuvant/adjuvant treatment of patients with resectable Phase III non-small cell lung cancer using the combination of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) and platinum-containing chemotherapy under the comparison with the combination of placebo and platinum-containing chemotherapy was approved by the National Medical Products Administration and was accelerated for patient registration.

Honors in 2023

On December 21, 2023

On December 21, 2023, the Company was awarded the "Outstanding Big Health Enterprise of the Year" at the Annual Excellence Company Award Ceremony of the Global Investment Carnival held by www.gelonghui.com.

On December 27, 2023

On December 27, 2023, the Company was selected as an "Excellent Case of ESG Pioneer Practitioner" at the “2023 Environmental, Social and Governance Development Exchange Conference with a Theme of Reshaping Enterprise Value and Building an ESG Ecosystem with Chinese Characteristics" held by Securities Daily.

In November 2023

In November 2023, the Company was included in the "Top 100 Chinese Pharmaceutical Innovation Enterprises" and "Top 20 Listed Companies in Chinese Pharmaceutical Industry with ESG Competitiveness" jointly selected by Healthcare Executive and third party independent agents. This is the second consecutive year that 3D Medicines had been awarded the title of "Top 100 Chinese Pharmaceutical Innovation Enterprises", and is also the first time that the Company had won ESG related awards since its listing. At a time when ESG performance is increasingly attracting the attention of consumers, regulators and investors at home and abroad, winning this honor is undoubtedly a recognition of the Company's ESG work at the present stage. The Company will continue to follow the development direction of society and the times, and strive for the goal of building a world-class pharmaceutical company.

On May 17, 2023

On May 17, 2023, 3D Medicines was awarded the "Top Ten Tumor Black Technologies of the Year" and "High-growth Enterprise of the Year" on the "Third Cool Techs for Oncology (CTO)" jointly organized by the Beijing Xisike Clinical Oncology Research Foundation (CSCO), Liangyihui and SciValuehub.

ESG

ESG concept

The Company actively practices the concept of sustainable development, fully understands the role and responsibility of enterprises in society, and continuously provides high-quality and effective innovative cancer drugs for patients, making contributions to society and human health. The Company will also continue to strive to improve its environmental, social and governance levels, and build a first-class and trustworthy innovative biomedical company in all aspects.

Management architecture of the Board of Directors

As the highest decision-making body of ESG work, the Board of Directors of the Company is responsible for ESG implementation policies, work strategies, risk identification and the formulation of sustainable goals, as well as the monitoring of the implementation of the ESG work and the annual ESG results.

The Board of Directors appoints the Board Office as the implementation and supervisory body for planning the overall ESG work, identifying and evaluating the Group's ESG-related content, supervising the daily ESG performance and implementation, evaluating ESG risks and establishing an effective internal communication mechanism.

The ESG work team is the actual execution department of the Company's ESG work, which conducts unified overall receipt, collation, and reporting of ESG matters. ESG work team directly communicates with various departments on the implementation and progress of ESG content, and publicly discloses ESG-related events.

All functional departments cooperate with the ESG work team to execute and implement ESG work plans and goals.

Statement of the Board of Directors

Responsibilities of the Board of Directors

As the highest responsible body of ESG architecture, the Board of Directors is responsible for formulating the Group's overall ESG strategies and goals, regularly monitoring, reviewing and approving ESG strategies and activities, identifying and approving major ESG risks and topics, timely disclosing ESG to the public, and reviewing negative ESG events.

Major ESG topics

The Company attaches great importance to the identification of major ESG topics, and finally confirm the content of major ESG topics through visits and investigations of various stakeholders and the evaluation of the Company's management.

ESG execution

The Company appoints the Board Office as the review, supervision, and execution body for ESG activities. The Board Office establishes an ESG work team as the specific execution body, which is responsible for achieving the Company's ESG strategies and goals, identifying ESG risks, and managing the specific progress and implementation of ESG work together with other functional departments.

ESG risk management

The Board of Directors pays close attention to ESG-related risks and sets up special personnel to monitor the Company's public opinion. The Company develops a series of risk response strategies, including risk discovery, identification, evaluation and treatment, to minimize the negative impact of ESG risks on the Company.

Communication with stakeholders

Stakeholders	Customers/potential customers	Shareholders and investors	Employees	Suppliers	Competitors	Government and supervisory body	Community
Expectation and requirements	◇ Product quality ◇ R&D innovation	◇ R&D innovation ◇ R&D progress ◇ Commercialization ◇ Information disclosure ◇ Shareholder's equity ◇ Intellectual property protection ◇ Risk governance	◇ Employee benefit ◇ Employee training ◇ Employee health and welfare	◇ Company procurement ◇ Procurement management	◇ Fair competition ◇ Win-win cooperation	◇ Responsible operation ◇ Corporate governance ◇ Promotion of industry development ◇ Sustainable development ◇ Social welfare	◇ Sustainable development ◇ Social welfare
Company response	◇ Quality management ◇ Study and innovation ◇ Responsible publicity ◇ Responsible operation	◇ R&D and innovation ◇ Quality management ◇ Intellectual property protection ◇ Commercial cooperation ◇ Responsible operation ◇ Supply chain management	◇ Employee rights and interests ◇ Employee health and safety ◇ Employee training and career development ◇ Compliance employment ◇ Employee equality ◇ Diversification ◇ Employee communication	◇ Supply chain and supplier management	◇ Responsible operation ◇ Commercial cooperation	◇ Responsible operation ◇ Emission management ◇ Natural resources management ◇ Social welfare ◇ Business ethics	◇ Social welfare ◇ Emission management ◇ Inclusive healthcare ◇ Natural resources management
Main communication modes	◇ Daily operation ◇ Company website ◇ Media message ◇ Academic conferences ◇ Industry forums	◇ General Meeting of Shareholders ◇ Investor roadshow ◇ Interim conference call ◇ Business progress news release ◇ Clinical data release and interpretation ◇ Securities communication ◇ Company website ◇ Performance announcement ◇ Interim and difficulty financial report ◇ Material disclosure	◇ Team building activities ◇ Employee training ◇ Performance evaluation ◇ One-to-one communication ◇ Exit interview	◇ Daily operation ◇ Supplier access ◇ Supplier procurement request ◇ Supplier audit	◇ Intra-industry exchange ◇ Industry conference discussion ◇ Strategic cooperation	◇ Government communication ◇ Regulatory communication ◇ Compliance review and report	◇ Public welfare activities ◇ Internal economizing system

Analysis of substantive topics



Substantive topic matrix of the Company

Highly important topics	16 R&D and innovation	7 Optimized resource management	8 Employee rights and interests	5 Energy saving
	27 Protection of the interests of shareholders and investors	9 Employee health and safety	2 Management of hazardous emissions	18 Supply chain management
	17 Intellectual property protection	20 Drug quality management	6 Response to climate change	
Moderate important topics	22 Responsible marketing	25 Legal and compliant governance	1 Sound environmental management system	4 Water resource utilization
	14 Legal employment, equality and diversity	11 Employee welfare and care	28 Anti-corruption and clean government	12 Employee training
	3 Chemical drug management	24 Economic benefits and financial performance	10 Employee communication	13 Employee salary
	26 Risk control	15 Customer service guarantee	19 Win-win cooperation	23 Social public welfare investment

Communicate with investors

Since its listing in 2022, the Company has focused on establishing long-term and effective communication mechanisms with investors. In 2023, the Company expanded various ways and channels to establish contact with investors, including media, forums, conferences, hotlines, etc. The Company helps investors understand the latest development and status of the Company through various channels such as roadshows, securities exchange meetings, and performance conferences, and answers the most concerned questions of investors. During the reporting period, more than 30 investor communication meetings were held.

At the same time, the Company has also strengthened its contact with individual shareholders. Through the establishment of corporate accounts in major trading software, the Company timely discloses the Company's information and dynamics, and carefully reads investor messages, and replies them when necessary.

In 2023

Conducted investor communication meetings more than

30

media

forums

conferences

hotlines

01

Environmental Management

Integrated environmental management

Pharmaceutical companies face a series of challenges and responsibilities in environmental management, so it is very important to establish an effective environmental management system. In order to promote standardized management and formulate relevant policies and goals, 3D Medicines continuously strives to reduce pollutant emissions, improve resource utilization efficiency, decrease energy consumption, and optimize integrated environmental management.

Environmental management system

According to relevant laws, regulations, and regulatory systems such as the Law of the People's Republic of China on the Prevention and Control of Environmental Solid Waste Pollution and the actual situation, 3D Medicines has formulates and implements an environmental management system with the aim of strengthening hazardous waste management, protecting the ecological environment, safeguarding human health, and maintaining public safety.

In order to further optimize environmental management, 3D Medicines clearly defines its environmental management goals, and promises to continuously reduce environmental pollution, practice resource conservation and recycling, actively carry out energy management and ecological protection, strengthen green supply chain management and environmental risk prevention.

The environmental management measures carried out by 3D Medicines include:

- **Regularly conduct resource consumption and clean production audits**: Evaluate and optimize resource utilization efficiency, reduce waste, and promote the R&D of clean production technologies through audits.
- **Conduct environmental impact assessment and review**: Conduct an environmental impact assessment on new, renovation and expansion projects, and ensure that their impact on the environment is fully considered and managed.
- **Conduct internal inspection and environmental audit**: Investigate and address environmental issues in the operating area through site survey and special inspection, and ensure environmental compliance.
- **Establish an environmental management system**: Formulate environmental policies, conduct environmental risk assessments, training and awareness raising, monitoring and reporting, and comprehensively manage environmental affairs.

In 2023

The Company had no major environmental problems or environmental protection punishments.

Emissions management

3D Medicines attaches great importance to emissions management, strengthens the supervision of pollutant emissions, ensures the standard discharge of wastewater and exhaust gas, standardizes the management and disposal of solid waste, and continuously improves the environmental protection awareness of employees in green emission reduction.

Compliant emission

3D Medicines strictly abide by the national and local environmental protection laws and regulations, adheres to the optimization of industrial structure, takes the development of circular economy as the guidance, and continues to promote the Company's clean production and reduce the Company's waste emissions, and improve the overall added economic value of the Company. All the R&D centers of the Company meet the requirements of local wastewater, waste gas, solid waste and other emission standards.

Ambient air	According to the Functional Zoning of Ambient Air Quality in Shanghai (HHBF [2011] No. 250), the Company is located in a class II ambient air zone, where the basic pollutants shall be subject to the Ambient Air Quality Standard (GB3095-2012) and its revised single secondary standard; while other pollutants shall be subject to the recommended values in Appendix D of Technical Guidelines for Environmental Impact Assessment - Atmospheric Environment (HJ2.2-2018) and the Detailed Explanation of Comprehensive Emission Standards for Atmospheric Pollutants.
Surface water environment	According to the Functional Zoning of Water Environment Quality in Shanghai (Rev. 2011), the Company is located in a class V water quality area, and subject to the class V standard of the Surface Water Environment Quality Standard (GB3838-2002).
Exhaust gas emission standard	The exhaust gas emissions are mainly particulate matters, and shall be subject to the Control Standard of Particulate Matter for Construction (DB31/964-2016), with the specific indicators shown in Table 18.
Wastewater discharge standard	The wastewater discharge shall be subject to the corresponding standards for indirect discharge by biomedical R&D institutions in the Discharge Standard of Pollutants for Bio-pharmaceutical Industry (DB31/373-2010) in Shanghai, as detailed in Table 20.
Solid waste	The general industrial solid waste storage sites shall comply with the requirements of the Standard for Pollution Control of General Industrial Solid Waste Storage and Disposal Sites (GB18599-2001) and its amendment in 2013; Hazardous waste storage sites shall comply with the requirements of Standard for Pollution Control on Hazardous Waste Storage (GB18597-2001) and its amendment. The storage capacity of hazardous waste shall meet the relevant requirements of the Notice of Shanghai Municipal Bureau of Ecological Environment on Issuance of the Implementation Plan for Further Strengthening the Prevention and Control of Hazardous Waste Pollution in Shanghai (HHT (2020) No. 50).

Management of hazardous waste

The legal person of the Company is the main responsible person for hazardous waste management. Members of the Biosafety Committee implement unified supervision and management of the Company's hazardous waste and environmental pollution prevention and control work. In term of the management of hazardous waste, the Company follows the principle of “unified collection, classified disposal, centralized incineration, and hazard cleanup”, and continuously promotes the achievement of the goals of "minimization, recycle and harmlessness" of hazardous waste.

The Company has incorporated pollution prevention and control of hazardous waste into its development plan, and organized the construction of collection and storage sites and specialized facilities that meet environmental protection requirements. The safety and environmental protection managers promptly report and register the relevant information of the Company's hazardous waste to the local environmental protection bureau, and log in to Shanghai Hazardous Waste Management Information System every year for hazardous waste declaration and registration. At the same time, the Biosafety Committee conducts annual maintenance on hazardous waste collection and storage sites and transportation facilities. If any damage is found, measures are taken to clean and replace it in time.

For transportation management, the local environmental protection department designates professional qualified transportation companies responsible for hazardous waste transport. If there are no specialized transportation vehicles, timely disinfection and cleaning shall be carried out in the centralized disposal site of hazardous waste. The Company's Biosafety Committee shall sign an agreement with transportation companies or individuals to prevent transportation leaks and spills, and supervise and inspect transportation companies and vehicles.

The Company has also established a hazardous waste accident reporting system, aiming to timely grasp environmental accidents and strengthen environmental supervision and management. Environmental accidents are divided into quick reports and disposal result reports. Quick report refers to the report of environmental accidents within one hour; the disposal result report refers to the report of environmental accidents immediately after the accident is resolved. In case pollution accidents or other sudden pollution accidents occur during the collection, transportation, storage, utilization, and disposal of hazardous waste, relevant units and individuals shall immediately take measures to prevent or reduce pollution hazards. They shall promptly report the situation to units and residents who may be affected by pollution hazards according to the actual situation, and also report to the local environmental protection department of the accident site.



Take measures to prevent or mitigate pollution hazards

Management of other emissions

In terms of emission management, the Company strictly controls the discharge of various pollutants, including the treatment and disposal of exhaust gas, wastewater, and waste residue. The Company adopts advanced pollution control technique and equipment to effectively reduce pollutant emissions and ensure compliance with relevant regulations and standards. In addition, the Company strengthens source control by optimizing production processes and adopting clean production methods to reduce waste generation.

The solid waste generated by the Company mainly comes from office waste and household waste in the production and operation process. To achieve effective management of office waste and household waste, the Company reduces the impact of waste on the environment through sorted collection. In addition, the Company advocates the use of reusable materials and containers, such as paper and plastic, to reduce waste generation.

In 2023, the Company has further strengthened its waste and emissions management by installing waste measurement instruments at its main operating locations and conducting regular internal supervision and management. Therefore, based on 2022, relevant data was more accurately collected and disclosed.

Indicator	Unit	2023	2022	2021
Total amount of hazardous wastes	Ton	43.71	3.16	2.50
Hazardous waste discharge density	Ton/million revenue	0.069	0.005	0.004

Coordinate energy conservation and emission reduction

Resources serve as the material basis for the existence and development of human society. Adhering to the development concept of environmental protection, energy saving and consumption reduction, 3D Medicines has been deeply grasping the internal relationship between energy development and ecological civilization construction, strengthening the management of hydropower, electric energy and other resources, comprehensively enhancing employees' awareness of saving within the Company, optimizing daily management, and making solid progress in the development of environmental protection and energy conservation.

Energy saving and consumption reduction

Strictly abiding by the provisions and requirements of laws and regulations such as the Law of the People's Republic of China on Energy Conservation, 3D Medicines always implements the concept of resource conservation in the enterprise production and operation, measures and monitors energy consumption, systematically records energy usage data, and standardizes energy management. Meanwhile, according to the national environmental protection laws, regulations, guidelines and policies, the Company has formulated the Management System for Energy Saving and the Management System for Water Saving in combination with its actual operation situation and development strategy, so as to constantly improve the energy management system, make rational use of resources, and improve the energy utilization rate.

Case

In the design and construction phase of Xuzhou plant of 3D Medicines, the environmental impact was fully considered in 2023. The Company will prepare relevant environmental management system documents according to the actual operation situation of the plant in the future, and formulate and strictly implement energy-saving measures to reduce the consumption of electricity and water resources in the operation, and will further prepare the relevant environmental management system documents according to the operation of the plant.

Specific energy-saving measures

The Company supervises laboratory and office staff to carry out energy-saving and consumption reduction work by posting warning signs and other means, for example, turn off lights when leaving, turn off air conditioner, facilities and equipment, and save more resources. Meanwhile, the management conducts supervision from top to bottom and deeply cultivates the concept of energy conservation. For example, we criticized and educated personnel on each floor who have not turned off lighting and air conditioner after work. In this way, we constantly deepen employees' awareness of energy conservation and reduce resource waste. In 2023, the Company's total electricity consumption decreased by 36.20% year-on-year.

In 2023, the Company's total electricity consumption decreased by 36.20% year-on-year.

Energy management

3D Medicines always attaches importance to the importance of energy management for sustainable development, and strictly abides by the provisions of the Law of the People's Republic of China on Energy Conservation; moreover, it also focuses on reducing unit energy consumption, supporting energy conservation development, and improving energy efficiency, and implements standardized energy conservation supervision and management within the Company, and implements energy conservation throughout the whole process of production and operation, so as to promote comprehensive, coordinated and sustainable economic and social development.

In 2023, the Company urged employees to save energy by posting warning signs, turning off lights, air conditioner and other equipment when leaving. The management also supervised and criticized personnel on each floor who have not turned off lighting and air conditioner after work, deepening their energy-saving awareness, reducing energy waste, and achieving a significant reduction in energy consumption.

Indicator	Unit	2023	2022	2021
Total electricity consumption	Kilowatt-hour	723,926	1,134,615	615,617
Energy efficient	kWh/RMB 10,000 revenue	11.40	20.00	10.22

Note: (1) The statistical data above involve 3D Medicines and its physical production subsidiaries in China.

Water resources management

Strictly abiding by the provisions and requirements of relevant laws and regulations such as the Water Law of the People's Republic of China, 3D Medicines advocates the rational use of water resources, continuously improves the recycle rate of water resources, improves the water-saving awareness of employees by promoting the concept of water conservation, so as to boost the construction of water-saving industry.

During the reporting period, the Company valued the use and consumption of resources from management to grass-roots employees, and we reduced water resource consumption through methods such as posting warning signs and management supervision.

Indicator	Unit	2023	2022	2021
Municipal water supply consumption	m^3	2,735.70	10,891.00	3,141.00
Barrelled water consumption	m^3	28.68	25.13	21.08
Bottled water consumption	m^3	4.87	0.88	0.88
Total water consumption	m^3	2,769.20	10,917.01	3,162.96
Water consumption intensity	m^3/RMB 10,000 revenue	0.04	0.19	0.05

Note: (1) Water efficiency can reflect the revenue per ton of water resource output, namely, the larger the output value per unit of water resource, the higher the water efficiency.
(2) The annual revenue data of 3D Medicines is from the H-share 2023 Annual Results Announcement.
(3) The data only involves 3D Medicines and its main subsidiary factories in China.

Material management

The business of 3D Medicines focused on drug R&D and clinical trials, and the materials were mainly used in the development and experiment of drug preparations. Actively responding to the "Dual Carbon" goal, the Company strengthens the control of the consumption of all kinds of pharmaceutical materials and packaging materials, reduces waste, and strengthens the recycling of packaging materials, and performs reasonable resource recovery of materials that cannot be recycled. The Company has maximized the resource environmental protection under the Material management premise of ensuring safe operation and no pollution. As of the end of 2023, the use of packaging materials by 3D Medicines has been entrusted to a third party for production and disposal, so there is no involvement in the consumption of packaging materials.

Ensure safe operation and no pollution

Maximize the resource environmental protection

Responding to the "Dual Carbon" strategy

Actively responding to national policies, 3D Medicines practices the concept of sustainable development with practical actions, pays attention to the protection of environmental ecology in the daily production activities and operation process, and controls greenhouse gas emissions in strict accordance with the relevant requirements of laws and regulations, contributing to the goals of carbon dioxide peaking and carbon neutrality.

Protect green homeland

3D Medicines constantly improves the prevention and control measures of air pollution to avoid negative impact on the environment, and strictly abides by the Law of the People's Republic of China on the Prevention and Control of Air Pollution and other laws and regulations; in addition we also take low-carbon development as an important driving force to improve quality and efficiency under the new normal, strictly control the total emissions of greenhouse gases, and enhance the low carbon competitiveness.

The greenhouse gas emission generated within the physical boundaries of production, operation and office of 3D Medicines mainly includes the two types of direct emission and indirect emission. The scope of cooperate operation does not involve direct emission sources; the main indirect source of emissions is purchased electricity.

Enhance the low-carbon competitiveness.

No.	Indicator	Unit	2023	2022	2021
1	Direct emissions (Category 1)	tCO_2e	-	3,087.61	-
2	Indirect emissions (Category 2)	tCO_2e	412.85	659.21	357.67
3	Total GHG emission	tCO_2e	412.85	3,746.82	357.67
4	GHG emission intensity	tCO_2e/RMB 1 million revenue	0.07	0.07	5.94

Note: (1) Direct emissions (Category 1) refer to the greenhouse gas emissions from the combustion activities of fossil energy, such as coal, natural gas and oil and industrial production processes;
(2) Indirect energy emissions (Category 2) refer to greenhouse gas emissions from the purchased electricity and heat;
(3) The accounting of calculations is based on the HKEX Environmental, Social and Governance (ESG) Reporting Guide, and the National Development and Reform Commission's Guideline for Accounting and Reporting Greenhouse Gas Emission of Other Industrial Enterprises.

Response to climate change

The increasingly aggravated global climate change has brought about challenges and opportunities for the Company to actively response to. In this context, the Company referred to the Task Force on Climate-related Financial Disclosures (TCFD) framework in 2023 to identify and assess the relevant climate risks and build a management system for climate change. By identifying the risks and opportunities related to climate changes, the Company made targeted response strategies to comprehensively enhance the climate adaptation capacity. Meanwhile, 3D Medicines will also accelerate the transition to a low-carbon economy, reduce carbon emissions and promote sustainable development. 3D Medicines will continue to improve management, actively respond to the challenge of climate change, and contribute to the enterprise sustainable development.



Risk name	Risk description	Solutions
Policies and regulations	The government has issued new policies and regulations to address climate change and strengthen the compliance requirements of environmental management.	Closely follow up changes in climate change related policies and regulations, and establish a sound compliance management system; regularly evaluate the impact of policy and regulatory risks on the Company, develop corresponding risk response strategies, and reduce the adverse effects of risks.
Reputation	A company's actions on climate change that are not aggressive enough or are perceived to have a negative impact on the environment can lead to a negative public perception of it, which can affect the company's reputation and image.	Take measures to reduce carbon emissions, improve energy efficiency, or promote sustainable development practices; develop and implement clear sustainable development strategies, strengthen environmental management, improve transparency, and effectively communicate with stakeholders.
Market risks	Climate change affects energy price fluctuations and pharmaceutical production costs; climate change may lead to changes in the prevalence patterns of certain diseases, thereby affecting the market demand for drugs.	Strengthen market monitoring and analysis, optimize supply chain management, increase R&D investment, promote green development, and enhance competitiveness and risk resistance.
Technical risks	As the impact of climate change intensifies, new technological standards and regulations may emerge, and existing technologies may not be able to adapt to the new challenges brought about by climate change.	Strengthen technological research and innovation, pay attention to changes in technological standards, actively engage in technological cooperation and exchange, and pay attention to the protection of intellectual property rights.
Acute physical risks	Physical losses and risks resulting from unexpected events, such as extreme climate events, natural disasters, and environmental accidents (e.g., typhoons, rainstorms, floods).	stablish an emergency response mechanism, strengthen the anti-disaster ability of infrastructure, establish flexible supply chains, optimize storage conditions, and develop emergency plans.
Chronic physical risks	Physical losses and risks resulting from the long-term and progressive effects of climate change (e.g. sustained high temperature, drought and sea level rising).	Develop long-term strategic planning, carry out comprehensive risk assessment, and analyze the potential impact of chronic physical risks on the enterprise; strengthen monitoring and early warning of climate change and environmental change.

Green and low-carbon operation

Adhering to the concept of green development, 3D Medicines adheres to the development strategy of green operation, integrates the concept of green and low carbon into the production and operation and daily office, strengthens the environmental protection education of employees, and encourages employees to practice green office; optimizes the packaging materials of the Company's products to reduce energy consumption; and creates a green industry chain as the goal, and promotes the recycling of energy, so as to build an environmentally friendly company.

Environmentally friendly and energy-saving buildings

Starting from various aspects, the Company strives to reduce its negative impact on the environment. During the construction process of the laboratory, environmentally friendly building materials, sound insulation and heat insulation materials are selected to minimize building energy consumption. In the production process, energy-saving equipment and clean energy are used to reduce energy consumption and carbon emissions. On the other hand, the Company optimizes production processes to reduce waste generation, and classifies and recycles waste.

Laboratory fresh air risk control system of 3D Medicines (Beijing)

Sewage treatment system of 3D Medicines Shanghai

Advocate low-carbon life

3D Medicines strengthens environmental protection training for employees, advocates green office and green lifestyle, promotes energy-saving, water-saving, paper-saving, green travel, etc., and cultivates employees' environmental awareness. While protecting the environment, we strive for green and low-carbon operations to continuously enhance our sustainable development capabilities.

The Company continues to promote paperless office models, encourages and supports video conference, establishes and improves information management systems, and facilitates online approval and reimbursement processes. In this way, we work hard at minimizing the resource consumption of office supplies and energy consumption in the workplace to the greatest extent possible. At the same time, the Company advocates for employees to develop good habits of water and electricity conservation by setting up relevant warning signs in prominent positions, using efficient and energy-saving lighting fixtures in the office, and strictly controlling the temperature of air conditioner to avoid energy waste. Triple faucet is used in the laboratory, which can improve the utilization efficiency of water and reduce waste.

Green supply chain management

Green supply chain management is a crucial component of environmental management in pharmaceutical companies. We collaborate with suppliers to guide and supervise their improvement in environmental sustainability, continuously promote green supply chain construction, and work together to reduce the environmental impact of the entire supply chain.

02

Innovative R&D

R&D management system

As an innovative pharmaceutical company, R&D capability has always been the core competitiveness of 3D Medicines. Therefore, we are committed to establishing a comprehensive R&D management system, providing prerequisites and important guarantees for the improvement of our R&D capabilities.



In terms of R&D management system, the Company, guided by unmet clinical needs, always performs drug R&D management with high-quality standards and continuously improving R&D management policies, ensuring that the products under study have sufficient clinical value worth exploring from beginning to end. During the reporting period, in order to achieve more efficient R&D management, improve innovation level and competitiveness, the Company established a new R&D center to manage four functional departments, responsible for chemical drug R&D and management, biomacromolecule R&D and management, R&d and management of mRNA tumors and new product development. The R&D center is directly managed by Dr. Gong Zhaolong, Chairman and CEO of the Company, to further improve the efficiency and effectiveness of R&D management.

Innovation platform construction

The Company has established a variety of drug R&D platform and continued to explore in the field of chronic cancer treatment. Relying on the Company's proprietary R&D platform, the Company can carry out preclinical R&D activities, including drug activity screening, drug cell function study, drug biochemical study and biomolecule detection.

The Company's R&D platform has strong molecular screening and design capabilities to improve the success rate of molecules from preclinical study to market, achieve innovative therapeutics and support pipeline assets built around key pathways and targets.

The Company's R&D centers in Shanghai and Beijing include large and small molecule platforms, cell line screening platforms, and compound screening platforms, mRNA R&D platforms, etc.



The Company has hundreds of commercial cancer cell lines from ATCC, ECACC, JCRB and RIKEN, the world's four largest cell banks. The source of cell cancer covers cancer types with high prevalence in the United States, Europe and Asia, such as lung cancer, liver cancer, colon cancer, stomach cancer, esophageal cancer and breast cancer, which can provide a broader, more effective and more convenient screening of candidate drugs in early preclinical R&D, and these samples also show significant advantages in the development of cancer biomarkers.

Construction of R&D team

R&D personnel are the core assets of a company, and excellent and experienced R&D personnel can help a company develop faster. Therefore, we are committed to building a high-quality, excellent, experienced, and promising R&D team. From the overall composition of R&D personnel, the Company is more inclined to introduce talents with master's degrees or above, accounting for 43% of the total R&D personnel, and talents with doctoral degrees accounting for 10%. We also pay special attention to the cultivation of young researchers, with 24% of R&D personnel being under the age of 30.



R&D and industrialization base

The Company is striving to improve its own R&D and production capacity, and actively build an industrial model integrating study and production. The Company is constructing internal production facilities in Xuzhou City, Jiangsu Province. The manufacturing system and facilities for the entire drug development process (including chemical and biological agents) comply with current good manufacturing practices (cGMP) and meet strict global standards. To prepare for the large demand for drugs after commercialization, we have purchased land use rights with a total area of 65,637.97 m^2 in Xuzhou. The Company has obtained a construction permit and started constructing new production facilities in Xuzhou City.

- Improve the own R&D and production capacity
- Actively build an industrial model integrating study and production

Business cooperation

The Company always maintains an open and win-win philosophy in cooperation, draws on each other's strengths utilizing our mature product R&D experience and advantages, discusses new technologies and ideas with partners, and improves the commercial competitiveness of the Company and partners through cooperation, building a sustainable upstream and downstream cooperation model. During the reporting period, the Company signed cooperation agreements with INNOLAKE BIOPHARM, CanSinoBIO, SINO-CELL BIOMED, and Novatim to cooperate in drug R&D. We completed licensing cooperation with Glenmark, granting exclusive licensing rights to the development and commercialization of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) for tumor indications in India, Asia Pacific (excluding Singapore, Thailand and Malaysia), the Middle East and Africa, Russia, CIS and Latin America, in order to benefit patients in more parts of the world.

Drug accessibility

Hoping to make every patient have access to drugs that are at the forefront of the world and meet different clinical needs, the Company always believes that drug R&D shall develop drugs that meet the needs of patient and are easily accessible from the perspective of the accessibility of drugs. Therefore, the Company improves the accessibility of its products in terms of continuous discovery of clinical needs, acceleration of clinical trials and drug marketing, expansion of drug sales channels, etc., striving to benefit the public.

During the reporting period, we actively sought cooperation in drug export and completed licensing cooperation with Glenmark in India in early 2024, granting exclusive licensing rights to the development and commercialization of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) for tumor indications in India, Asia Pacific (excluding Singapore, Thailand and Malaysia), the Middle East and Africa, Russia, CIS and Latin America. This will enable our drugs to benefit more countries, especially some developing and underdeveloped countries, so that more people in need can benefit from our drugs.

In 2023, we also collaborated with multiple biological companies to jointly develop drugs including mRNA, TIL, CAR-T, and ADC, or to collaborate on projects with 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1). Utilizing our own advantages, we collaborate with other companies and actively explore the world's cutting-edge pharmaceutical technology fields to diversify our products and to help our patients benefit more.

In the process of commercialization, we also regard drug accessibility as our top priority. During the reporting period, 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) was available in 36 cities and listed in the people-benefit insurance (urban customized commercial medical insurance) in 2023, with a channel network covering 30 provinces, 312 cities, 1,300 hospitals, and 1,100 pharmacies. The sales team of 恩維達® (Envafolimab, Subcutaneously-Injectable PD-L1) has reached about 1,000 people, with 100 full-time employees and 900 mixed line employees. This makes our products as accessible as possible to patients across the country. In 2023, we provided over 20,000 drugs for cancer patients, allowing them not only to access the products but also to afford them.

Intellectual property protection

In the early days of the company, we have gradually established intellectual property management systems such as the Patent Management System, Trademark Management System, and Copyright Management System according to the standards of intellectual property management, and continuously modified , supplemented, and improved them in subsequent operations according to cooperate development situation. In 2023, we further improved the patent application approval process in accordance with the Patent Management System, making patent management more reasonable and conducive to the scientific and effective application of patents and the protection of our R&D achievements.

By the end of 2023, the Company had obtained a total of 31 patents, 85 registered trademarks, and 28 copyrights. In 2023, the Company applied for 5 new patents and 5 new trademarks. In 2023, the Company obtained 6 authorized patents and registered 13 trademarks.

registered trademarks
85



03

Quality Management

Quality management system

We strictly abide by the Drug Administration Law of the People's Republic of China, Measures for the Supervision and Administration of Drug Production, Measures for the Administration of Drug Registration and other relevant laws, regulations and provisions, and carry out research and manufacture of investigational new drugs in accordance with the Good Manufacturing Practice of Medical Products (GMP), Good Clinical Practice (GCP) and Good Laboratory Practice for Non-clinical Laboratory Studies (GLP).

The Company entrusts manufacturers for production of its products and currently has no actual production operations, so there is no work safety organization system or work safety system. The Company, according to Standard Management Procedures for OEM on Drugs, conducts quality audits on entrusted manufacturers every six months. In addition, in order to ensure the quality and safety of drugs, the Company conducts on-site supervision and inspection on entrusted manufacturers. In accordance with the Standard Management Procedures for Site Supervision and Inspection of OEM on Drugs, we inspect all key processes, quality control laboratories, storage systems, and public facilities of entrusted manufacturers every two quarters. In 2023, the Company suffered zero lost due to employee injuries in production and operation positions. The Company currently has no production equipment, so there is no depreciation and scrapping policy for equipment, and no production equipment management and maintenance system.

- Key processes
- Quality control laboratories
- Storage systems
- Public facilities

2023

In 2023, the Company suffered zero lost due to employee injuries in production and operation positions.

Quality control

The Company has established a sound quality management system in strict accordance with the latest Provisions on the Supervision and Administration of the Fulfillment of Medicinal Product Quality and Safety Responsibilities by Holders of Marketing Authorization for Medicinal Products (2022, No. 126) and the Announcement of National Medical Products Administration on Strengthening the Supervision and Management of Marketing Authorization Holders' Entrusted Manufacture (2023, No. 132), and we have formed a quality assurance system for the entire drug production process, including the Management Procedures for Document, Management Procedures for Employee Training, Management Procedures for Suppliers, Management Procedures for OEM on Drugs, Management Procedures for Drug Marketing Release, Management Procedures for Product Sales, and Management Procedures for Handling User Complaints. In accordance with prepared Management Procedures for Corrective Actions and Preventive Actions prepared, the Company analyzes, evaluates, and investigates identified and potential non-conformances throughout the product lifecycle and management process, and takes corresponding corrective and preventive actions to fundamentally eliminate the causes of problems, prevent their recurrence, and achieve the goal of improving product processes, controlling quality risks, and continuously improving the quality system.

The Company's products belong to pharmaceutical category, so the quality management system for OEM on Drugs has passed the licensing inspection of NMPA, and we obtained the Drug Production License issued by NMPA.

Quality training

The Company has conducted multiple trainings for its main quality management personnel, with training contents covering quality standards, process technology, R&D technology, pharmacovigilance, etc. In 2023, 3D Medicines (Sichuan) Co., Ltd. (MAH), as the main production department of the Company, completed 9 trainings in total, including 3 regulatory training sessions, 2 technical training sessions, 2 process training sessions, 1 protocol training session, and 1 responsibility training session. Each training lasted about 1 hour and 84 person-time involved.

2023

- trainings completed in total: 9
- regulatory training sessions: 3
- technical training sessions: 2
- process training sessions: 2
- protocol training session: 1
- responsibility training session: 1
- each training lasted about: 1 h
- person-time involved: 84

The training topics are as follows:

Training topic	Training type	Training date
User complaint handling process and case analysis	Process	2023.01
Good Manufacturing Practice	Law and regulation	2023.03
Introduction to upstream processes	Technology	2023.04
Research on the stability of biological products	Technology	2023.06
Technical Guidelines for the Study of Pharmaceutical Changes in Marketed Biological Products (Trial)	Law and regulation	2023.07
Quality Agreement for OEM on Drugs	Protocol	2023.08
Training on key departments and job responsibilities (production and quality)	Responsibilities	2023.11
Introduction to pharmacovigilance quality system and audit work	Process	2023.11
Announcement on Strengthening the Supervision and Management of Marketing Authorization Holders' Entrusted Manufacture	Law and regulation	2023.12

The training pictures are as follows:





Customer service

Pharmacovigilance and customer complaints

The Company focuses on customer rights and services, attaches great importance to drug safety, and actively and comprehensively collects customer complaints and feedback. We strictly comply with relevant laws and regulations, and have developed an SOP for Management of Product Complaints (document No.: SLD-SMP-PV-029) through the Pharmacovigilance Department to ensure that the Company promptly and compliantly handles all product related complaints and implements necessary corrective and preventive actions. At the same time, the Company also perform supporting regulations such as Hotline Management (document No.: SLD-SMP-PV-028), SOP for Pharmacovigilance Off-hours Emergency Contact Telephone (document No.: SLD-SMP-PV-030), Procedures for Medical Consultation and Problem Solving (document No.: SLD-SMP-PV-013), Process for Responding to Questions Raised by Drug Regulators (document No.: SLD-SMP-PV-012), Processing Process of Data Information Feedback from Supervisory and Management Departments (document No.: SLD-SMP-PV-033), etc. As of now, a total of 33 customer complaints have been received, with the majority resolved and very few still being solved.

Customer privacy

The Company strictly complies with the relevant laws and regulations of the country on the protection of personal and organizational information, and the protection of customer information is integrated into all aspects of the Company's work and operation. The Pharmacovigilance Department has specially formulated SOPs such as SOP for Pharmacovigilance Personal Data Processing and Protection, which emphasize and attach great importance to the protection of personal information in all pharmacovigilance activities. No incidents of customer information leakage occurred.

Product recall process and handling mechanism

The Company has formulated the Standard Management Procedures for Drug Recall in accordance with the Administrative Measures for Drug Recall. The Quality Management Departments of the holder and the entrusted manufacturer jointly confirm the quality risks of the drugs. If safety hazards are found, an investigation will be immediately carried out. Finally, the person in charge of the holder's enterprise will decide whether to recall based on the investigation results.

Recall process: Formulate the recall plan and initiate recall after determining recall upon the assessment of drug safety hazards, issue the recall notice to the drug handling and use organizations, and record the recall plan, recall notice and potential quality safety hazards and report to the provincial drug administration within the prescribed time limit; store the recalled drugs separately, track the recall progress, and report to the provincial drug administration; and handle the recalled drugs under the supervision of relevant departments, summarize the whole recall process, and report the recall and handling situation to the local provincial drug administration and healthcare authority within the prescribed time limit, and close the recall and archive all data if there are no problems in all aspects.

The recall process diagram is as follows:



In 2023, the Company has no products that need to be withdrawn or recalled due to health and safety reasons.

Sustainable supply chain

Supply chain management

The commercial supply chain of the Company adopts cold chain transportation and supplier management to provide services. We have established a long-term and close cooperative relationship with CR PHARMA. Through information sharing and management of the supply chain work system with our partners, we manage warehouse management and logistics distribution, and achieve maximum competitiveness of the supply chain at the lowest cost.

Warehouse management

Adopting real time inventory monitoring, safety stock setting, etc., to ensure inventory costs, improve inventory turnover, etc. can meet market demand and avoid resource waste and other problems such as near-expired drugs and dull sale.

Logistics and delivery

We strictly review the transportation equipment and plans of our partners. The partners have complete qualifications and logistics systems, which can ensure that the drugs are safe under the specified temperature and humidity conditions at every stage from storage, transportation to delivery.

At the same time, we also attach great importance to risk management, and comprehensively identify and evaluate various risks that may arise during the operation of the supply chain, including supplier risk, inventory risk, logistics risk, etc. In response to these risks, we have developed corresponding response strategies and plans to reduce the likelihood and impact of risk occurrence, and minimize the losses caused by risks.

Supplier management system

We abide by the Government Procurement Law of The People's Republic of China, the Law of the People's Republic of China on Bid Invitation and Bidding and other relevant laws and regulations. Meanwhile, the Company has formulated management documents such as Procurement Management System, Service Provider Evaluation Form and New Supplier Information Form to continuously optimize the supplier management system. The Company adheres to the procurement mode of compliance, transparency and diversification, and actively communicates and cooperates with suppliers. We are establishing a reliable and competitive supply chain guarantee system with our suppliers.

Prior to the selection of suppliers, we will audit the qualifications of suppliers, fully consider the relevant impact of suppliers on the environment and society, incorporate the audit scoring mechanism, and conduct on-site inspection and audit as appropriate. The suppliers after qualification will be included in our supplier database. We implement annual audit system for suppliers, auditing their product and service quality, brand value, price, communication mechanism, flexibility, and order response speed. We eliminate the suppliers with low scores, so as to ensure the quality of suppliers and reduce the risk of suppliers.

As of the end of the reporting period, the Company has a total of 295 inbound suppliers from multiple regions and countries. The Company has conducted access review and regular verification for each supplier.

Location	Hangzhou	United States	Japan	Shanghai	Beijing	Nanjing	Guangzhou	Wuxi	Suzhou	Singapore	Switzerland	Shenzhen	Sweden	Netherlands	Kunming	Dongguan	Chengdu	Qingdao	Total
Number of suppliers	6	8	1	148	107	4	2	1	2	1	1	2	1	1	1	1	1	7	295

04

People First

Safeguard employee's rights and interests

3D Medicines strictly adheres to laws and regulations such as the Labor Law of the People's Republic of China and the Labor Contract Law of the People's Republic of China, effectively protects the rights and interests of employees and work safety, formulates competitive salary standards, and establishes a smooth path for career development.

Employment

The Company adheres to the principles of legal employment, people first, fair competition, and diversified employment, and formulates and continuously improves internal management systems such as the Recruitment Management System. It strictly prohibits the use of child labor, forced labor, and recruitment activities involving region, gender, and ethnic discrimination; if any, it will be dealt with in accordance with the rules and regulations. The Company strictly follows the employment process to ensure the introduction of high-quality, capable, and responsible talents. As of the end of 2023, the Company has 198 full-time employees.









Composition of employee turnover rate



Employee remuneration and benefits

We are committed to establishing an effective compensation system where the compensation level is related to the value, performance and potential of the position. The Company has formulated the Management Measures for Employee Remuneration and the Performance Management Standards. The salary adjustment, bonus and promotion of employees are all related to their work-related results.

The Company has formulated the Management Measures for Employee Remuneration to standardize and safeguard the benefits of employees. In addition to statutory benefits, the Company provides supplementary benefits for employees, such as allowance subsidies (transportation subsidies, lunch subsidies, communication subsidies, etc.), supplementary commercial insurance (medical insurance, accident insurance, etc.), paid sick leave, annual physical examination, department team building fund, continuing education incentives, holiday gifts, and consolation money.

The Company follows the legal working hour system and implements weekends off system; the Company arranges annual statutory holidays in accordance with national regulations, and employees enjoy normal salary and benefits during the statutory holidays; corporate employees are entitled to annual leave in accordance with the law, and the number of days of annual leave shall be implemented in accordance with the Implementation Measures for Paid Annual Leave for Employees of Enterprises, and during the annual leave period, employees shall enjoy normal salary and benefits; to ensure the physical and mental health of employees, the Company also provides them with 5 days of paid sick leave per year. Other paid leave also includes maternity leave, prenatal check-up leave, paternity leave, childcare leave, bereavement leave, etc.

Employee promotion

The Company insists on providing employees with fair and just channels for promotion and opportunities. In order to standardize post levels and promotion processes, the Company has formulated the Management Measures for Personnel Promotion. The Company's job qualification standards include dimensions such as work experience and educational experience, knowledge and skills, performance results, and comprehensive abilities. For personnel promotion, the principles of equal emphasis on ethics and performance, step-by-step promotion, and promotion/demotion are followed.

During the reporting period, 17 people in the Company completed job promotions and there were no layoffs.

During the reporting period

people in the Company completed job promotions

17

Employee training

To standardize training management, the Company has developed corresponding systems such as the SOP for Employee Training Management and the Management Measures for External Training and Examination.

In 2023, the Company conducted a total of 8 trainings for all employees, covering quality, compliance, finance, genetic knowledge management, pharmacovigilance, intellectual property, and research and development processes. The training results were evaluated. The average training duration is 1 - 1.5 hours, with over 100 attendees. Male employees completed approximately 408 hours of training, while females completed approximately 792 hours of training.

In addition, all new comers will be arranged to participate in new employee training within two weeks of entry. The Human Resources Department shall organize professional personnel from relevant departments to arrange training.

The Company has also formulated the Management Measures for External Training and Examination, aiming to encourage employees to accelerate self-improvement and enhance the competitiveness of the Company. In 2023, 9 colleagues participated in training organized by specific external organizations, including clinical, quality, and pharmacovigilance, and obtained corresponding certificates.

Employee occupational safety

Employee safety management

The Company clearly states in the Employee Handbook that employees have the right to work safety and protection. The Company believes that ensuring the health and safety of employees is an integral part of its operations, and ensures compliance with Chinese laws and good practices in health, safety, and environmental protection matters. The Company encourages employees to immediately report to their supervisors or relevant departments such as EHS, Human Resources Department, or administrative departments when they encounter, learn of, or notice potentially unsafe working conditions. At the same time, the Employee Handbook clearly states that employees not only have a duty of care for their own health and safety, but also for the health and safety of other employees who appear in the workplace during working hours.

Employee health and safety

In order to cope with relevant safety situations, the Company has formulated the Emergency Plan Management System, widely promoting emergency laws and regulations, prevention, risk avoidance and other common knowledge, and enhancing emergency awareness and emergency response capabilities. Personnel with emergency management responsibilities shall be trained in emergency plans and emergency knowledge in a planned way.

The Company actively cooperates with relevant departments and regularly organizes all employees to participate in emergency training such as fire drills.

In 2023

the Company lost

0 working day due to work-related injuries

0 deaths due to work-related injuries

The Company strictly abides by the Law of the Peoples Republic of China on Prevention and Control of Occupational Diseases and other relevant laws and regulations to protect the occupational health of employees. The Company guarantees the safety and health of employees by providing annual health check-ups, labor protection supplies, medical boxes and other measures.

Regarding the working environment, in addition to the provision of basic fire equipment, the Company carried out formaldehyde and other harmful substances detection and passed the tests. We installed facilities and equipment in the production environment, conducted hazardous substances testing, equipped emergency supplies, and timely checked and replaced defective equipment.

Employee care

The Company gives out a certain amount of condolence money to employees who are hospitalized due to illness during their employment and employees whose immediate family members have passed away; the Company has developed a Watch Plan to provide certain cost subsidies to employees or their relatives with tumors when they purchase tumor gene sequencing testing services.

Employee satisfaction

In 2023, one-on-one interviews and surveys were conducted with all formal employees currently employed. The interview involved work content, team collaboration, work environment, salary and benefits, management mechanisms, and development prospects. The Human Resources Department has truthfully recorded and summarized the interview results. Prominent issues were discussed at management meetings and corresponding solutions were proposed for addressing step by step.



During the reporting period

During the reporting period, the total employee turnover rate of the Company was 22%.

05

Community Construction and Engagement in Public Welfare

Our goal is to build a socially friendly enterprise, develop together with our community, and make contribution to society in various forms. At the same time, we take public welfare activities as a part of corporate culture, enhancing the Company's social value and making contributions to society as much as possible.

The donation related expenses of the Company for this year exceeded RMB **96** million.

Charitable drug donation

Cancer is a critical illness field that imposes a huge burden on patients, their families, and even society. As an company that dares to take on social responsibility and wholeheartedly serves cancer patients, 3D Medicines, in collaboration with the Beijing Health Alliance Charitable Foundation, continues to carry out patient assistance projects to assist cancer patients.

We provided over 20,000 drugs to cancer patients in 2023, helping them improve the effectiveness of cancer treatment, thereby reducing the pain and burden of the disease, reducing the social and family economic burden caused by the disease, and improving the quality of life and courage of patients to face the disease. In the future, we will continue to be enthusiastic about the development of cancer public welfare, help more cancer patients, and help them live longer and better.

During the reporting period

Provided over 20,000 drugs to cancer patients

06

Corporate Governance

Integrity has always been a top priority in the operation of enterprises in the pharmaceutical industry. The Company strictly complies with laws and regulations such as the Anti Unfair Competition Law of the People's Republic of China and the Interim Provisions on Prohibition of Commercial Bribery. During our operation, 3D Medicines always adheres to the Securities Law of the People's Republic of China and the Listing Rules and the Code of Corporate Governance for Listed Companies of HKEX. We continuously build a sound corporate governance mechanism and system, implement risk control and anti-corruption policies, safeguard our good reputation, and enable the Company to continue to develop in a healthy and sustainable manner.

Corporate Governance system

The Board of Directors of the Company is the core body of corporate governance, consisting of the Chairman, independent directors and non-independent directors. The independent directors account for more than one-third of the Board of Directors. The Board of Directors has three committees including the Audit Committee, the Remuneration Committee and the Nomination Committee to oversee the conduct of the Company's management and ensure the long-term development of the Company. Attaching great importance to the professional background and industry experience of the members composing the Board of Directors, the Company had 7 directors in 2023, including 1 Executive Director, 3 Non-executive Directors and 3 Independent Non-executive Directors, 3 of whom had doctoral degrees and 1 of whom was a female director. With rich industry experience and advantages in their respective fields, the members composing the Board of Directors of the Company can make correct decisions for the comprehensive development of the Company.

Internal control management

In accordance with the requirements for the establishment of a modern enterprise system, the Company has established a corporate governance structure based on enterprise risks and its own development situation, and set up an organization that meets the Company's business scale and operation management needs, and continuously improved and optimized the Company's internal control management system from the five aspects of control environment, risk assessment, control activities, information and communication and internal supervision, so as to ensure that the internal control system is effective and sound, and the responsibilities are clear.



Attaching great importance to the construction of internal control management system, the Company has formulated a series of company policies and processes involving sales, procurement, quality management, pharmacovigilance, legal and compliance, finance, internal audit, human resources, and IT. During the reporting period, in order to improve the risk and internal control awareness of management and employees, the Company provides online and offline publicity and implementation training for employees.

Risk control

The Company believes that a sound risk management system will contribute to its sustainable development. We attach great importance to the risks of all production and operation links of the Company, especially the major risks related to corporate strategy, purchase and sale of major assets, foreign investment and related-party transactions. Led by the board of directors, the Company's risk management system mainly consists of Legal & Compliance Department, Internal Control and Audit Department, and business departments and business teams. Relevant project approval meetings will be held for major risks, in which the members of Board of Directors, legal & compliance department, internal audit and related business departments will participate to jointly identify risk issues and consider potential risks and opportunities of the overall project, and the Board of Directors will give approval and make final decision after repeated deliberation and review.

Complaining and whistle-blowing ways

We have introduced the Management Measures for Whistle-blowing and Handling Improper Conduct (regulations for reporting procedures), and registered for a whistle-blowing E-mail (compliance@3D-medicines.com), and we encouraged employees to whistle-blow and complain about compliance and fraud to the Company, and protected the interests and privacy of whistleblowers to the greatest extent to ensure the fair and equitable treatment for them. Regarding any whistle-blowing and complaining information that need to be investigated upon preliminary confirmation, the legal and compliance department would organize, and jointly establish employee integrity files with the human resources department, and then launch an investigation after authorized by the CEO, and report and fed back the results to the Company's management.

In 2023

In 2023, the Company did not receive any anti-fraud related whistle-blowing information.

Training on combating corruption and upholding integrity as well as internal control risks

The Company organizes anti-corruption and compliance training for its employees every year to raise their awareness of compliance. In 2023, the Quality Management Department organized colleagues in the Legal & Compliance Department as the trainers to provide 2 training sessions. Multiple aspects are involved in the publicizing and implementation, and training of the relevant anti-commercial bribery systems of 3D Medicines, such as anti-commercial bribery management system, anti-money laundering management system, third party due diligence management system, misconduct whistle-blowing and handling management measures, meeting and activity policies, and typical cases in related fields in recent years. All employees of the Company actively participate in learning the relevant systems of anti-commercial bribery, and correctly comply with the relevant laws and regulations of anti-commercial bribery, thus better maintaining the image of the Company and fundamentally promoting the development of the Company.

training sessions provided in total

2

Appendix: Index to the Environmental, Social and Governance Reporting Guide issued by the Stock Exchange of Hong Kong Limited.

Main Category A. Environment

Main categories, levels, general disclosures, and KPIs			Disclosure section
Level A1: Emissions	General disclosure	Disclosure about relevant exhaust gas and greenhouse gas emissions, discharges into water and land, hazardous and non-hazardous waste: (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer.	Environmental management: Integrated environmental management Coordinate energy conservation and emission reduction Responding to the "Dual Carbon" strategy: Protect green homeland Response to climate change
	KPI A1.1	Emission types and relevant emission data.	Integrated environmental management: Pollution discharge management
	KPI A1.2	Direct (scope 1) and indirect (scope 2) greenhouse gas emissions from energy sources (in tons), and (where appropriate) intensity (e.g. per unit of production volume, per facility). Scope 1 Emissions	Responding to the "Dual Carbon" strategy: Protect green homeland
		Scope 2 Emissions	
	KPI A1.3	Total hazardous waste produced (in tons) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Integrated environmental management: Pollution discharge management
	KPI A1.4	Total non-hazardous waste produced (in ton) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Integrated environmental management: Pollution discharge management
	KPI A1.5	Description of the emission objectives set and the steps taken to achieve such objectives.	Integrated environmental management: Pollution discharge management
	KPI A1.6	Description of the method to dispose of hazardous and non-hazardous wastes, waste reduction objectives set and the steps taken to achieve such objectives.	Integrated environmental management: Pollution discharge management
Level A2: Use of Resources	General disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	Environmental management: Coordinate energy conservation and emission reduction
	KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (KWh in '000s) and intensity (e.g. per unit of production volume, per facility).	Coordinate energy conservation and emission reduction: Energy management
	KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	Coordinate energy conservation and emission reduction: Water resources management
	KPI A2.3	Description of the energy use efficiency objectives set and the steps taken to achieve such objectives.	Coordinate energy conservation and emission reduction: Energy management
	KPI A2.4	Description of any problems in obtaining the applicable water sources, the water use efficiency objectives set and the steps taken to achieve such objectives.	Coordinate energy conservation and emission reduction: Water resources management
	KPI A2.5	Total packaging material used for finished products (in ton), and, if applicable, proportion of per production unit.	Coordinate energy conservation and emission reduction: Material management

Main categories, levels, general disclosures, and KPIs			Disclosure section
Level A3: Environment and natural resources	General disclosure	Policies on minimizing the issuer's significant impact on the environment and natural resources.	Integrated environmental management: Environmental management system Responding to the "Dual Carbon" strategy: Response to climate change
	KPI A3.1	Description of significant impacts from business activities on the environment and natural resources and the actions taken to manage them.	Responding to the "Dual Carbon" strategy: Response to climate change
Level A4: Climate change	General disclosure	Identification and response to policies prepared for significant climate-related issues that have already had or may have an impact on the issuer.	Responding to the "Dual Carbon" strategy: Response to climate change
	KPI A4.1	Description of significant climate-related issues that have already had or may have an impact on the issuer and corresponding responsive actions.	Responding to the "Dual Carbon" strategy: Response to climate change

Main Category B. Society

Employment and Labor Practices

Main categories, levels, general disclosures, and KPIs			Disclosure section
Level B1: Employment	General disclosure	Relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare: (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer.	People first: Safeguard employee's rights and interests
Level B1: Employment	KPI B1.1	Total workforce by gender, employment type (full time or part-time), age group and geographical region.	People first: Employment
	KPI B1.2	Employee turnover rate by gender, age group and geographical region.	People first: Employment
Level B2: Health and safety	General disclosure	Disclosure about providing a safe working environment and protecting employees against occupational hazards: (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer.	People first: Employee occupational safety
	KPI B2.1	The number and ratio of work-related deaths annually in the past three years (including the reporting year).	People first: Employee occupational safety
	KPI B2.2	Lost days due to work injury.	People first: Employee occupational safety
	KPI B2.3	Description of occupational health and safety measures adopted, how they are implemented and monitored. Describe training activities.	People first: Employee occupational safety
Level B3: Development and training	General disclosure	Policies on improving employees' knowledge and skills for discharging duties at work.	People first: Employee training
	KPI B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management, etc.).	People first: Employee training
	KPI B3.2	Average training hours completed per employee by gender and employee category.	People first: Employee training

Main categories, levels, general disclosures, and KPIs			Disclosure section
Level B4: Labor standards	General disclosure	Disclosures about preventing child and forced labor: (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer.	People first: Employment
	KPI B4.1	Description of measures to review employment practices to avoid child and forced labor.	People first: Employment
	KPI B4.2	Description of steps taken to eliminate such practices when discovered.	People first: Employment
Level B5: Supply chain management	General disclosure	Environmental and social risk policies for supply chain management.	Product liability: Supply chain management
	KPI B5.1	Number of suppliers by geographical region.	Product liability: Supply chain management
	KPI B5.2	Description of practices relating to engaged suppliers, number of suppliers where the practices are being implemented and how they are implemented and monitored.	Product liability: Supply chain management
	KPI B5.3	Description of the practices used to identify the environmental and social risks at every stage of the supply chain and relevant implementation and monitoring methods.	Product liability: Supply chain management
	KPI B5.4	Description of the practices used to promote the use of green products and services at the time of selecting suppliers and relevant implementation and monitoring methods.	Product liability: Supply chain management
Level B6: Product liability	General disclosure	Disclosure about health and safety, advertisement, label and privacy matters relating to products and services provided and methods of redress. (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer.	Product liability: Quality management system Quality control Customer privacy

Main categories, levels, general disclosures, and KPIs			Disclosure section
Level B6: Product liability	KPI B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Product liability: Product recall process and handling mechanism
	KPI B6.2	Number of products and services related complaints received and how they are dealt with.	Customer service: Pharmacovigilance and customer complaints
	KPI B6.3	Description of practices relating to safeguarding and protecting intellectual property rights.	Innovative R&D: Intellectual property protection
	KPI B6.4	Description of quality verification process and product recall procedures.	Product liability: Product recall process and handling mechanism
	KPI B6.5	Description of consumer data protection and privacy policies and how they are implemented and monitored.	Responsible operation: Customer privacy
Level B7: Anti-corruption	General disclosure	Disclosure about bribery, extortion, fraud and money laundering: (a) Policies; and (b) Compliance with relevant laws and regulations and other materials that have a significant impact on the issuer.	Responsible operation: Compliance and anti-fraud management
	KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	Responsible operation: Compliance and anti-fraud management
	KPI B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	Responsible operation: Complaining and whistle-blowing ways
	KPI B7.3	Description of the anti-corruption training provided for the directors and employees.	Corporate governance Training on combating corruption and upholding integrity as well as internal control risks
Level B8: Community investment	General disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its business activities take into consideration the communities' interests.	Community construction and engagement in public welfare
	KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labor needs, health, culture, and sports).	Community construction and engagement in public welfare
	KPI B8.2	Resources (e.g. money or time) contributed to the focus areas.	Community construction and engagement in public welfare

Referral Table

The Company, we	referred as	3D Medicines Inc., an exempted company with limited liability incorporated under the laws of the Cayman Islands on January 30, 2018, the Shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 1244)
恩維達®	referred as	envafolimab (brand name: 恩維達®), a subcutaneously injectable PD-L1 inhibitor for the treatment of tumor-agnostic indications
BLA	referred as	biologic license application
NDA	referred as	new drug application
MRCT	referred as	multi-regional clinical trial
IND	referred as	Investigational New Drug
PROC	referred as	Platinum-resistant ovarian cancer
AML	referred as	acute myeloid leukemia, a type of cancer that progresses rapidly and aggressively, and affects the bone marrow and blood
MPM	referred as	Malignant pleural mesothelioma
OC	referred as	Ovarian cancer
MM	referred as	Multiple myeloma
mRNA	referred as	Messenger RNA
CDE	referred as	Center for Drug Evaluation, National Medical Products Administration
NMPA	referred as	National Medical Products Administration
CSCO	referred as	Chinese Society of Clinical Oncology
ESG	referred as	Environmental, Social and Governance
cGMP	referred as	Current Good Manufacturing Practice for Drugs
ELISA	referred as	Enzyme Linked Immunosorbent Assay
FDA	referred as	the United States Food and Drug Administration
PCR	referred as	Polymerase Chain Reaction
XtalPi	referred as	XtalPi

Referral Table

GMP	referred as	Good Manufacturing Practices, the existing guidelines and regulations issued in accordance with the Drug Administration Law of the People's Republic of China, as part of quality assurance, are designed to minimize the risks of contamination, cross-contamination, confusion and errors in the manufacture of pharmaceutical products, and ensure that drugs subject to such guidelines and regulations are continuously manufactured and controlled in accordance with the quality and standards applicable to the intended use
GCP	referred as	Good Clinical Practice
SOP	referred as	Standard Operation Procedure
GDPR	referred as	General Data Protection Regulation
R&D	referred as	research and development

Form of Reader's Feedback

Dear readers:
Hello!
Thanks for reading this report. We are sincerely looking forward to your valuable feedback and advise on the report so that we can continue to improve our work, enhance ESG management ability and upgrade ESG management standard! You may send us the questionnaire through mail or scan the questionnaire and send us a digital version through email. Your active feedback are most welcomed. Thank you!

Mailing Address:7 Liangshuihe 1st Street, Building 3-6, Yizhuang Biomedical Park, BDA, Beijing, China
Tel.:+86(10)6788 8635
E-mail:ir@3d-medicines.com

What kind of stakeholders of the Group do you work for?

☐ Shareholder and Investor ☐ Employee ☐ Supplier ☐ Customer ☐ Government and Regulator ☐ Community

☐ Partner ☐ Industry Association/NGO ☐ Others (Please specify)_____

Your overall rating of the Report:

☐ Good ☐ Fair ☐ Average ☐ Poor

How do you rate the clarity, accuracy and completeness of the information and data disclosed in the Report?

☐ Good ☐ Fair ☐ Average ☐ Poor

How do you rate the comprehensiveness of the economic responsibility undertaken by the Group reflected in the Report?

☐ Good ☐ Fair ☐ Average ☐ Poor

How do you rate the comprehensiveness of the environmental responsibility undertaken by the Group reflected in the Report?

☐ Good ☐ Fair ☐ Average ☐ Poor

How do you rate the comprehensiveness of the social responsibility undertaken by the Group reflected in the Report?

☐ Good ☐ Fair ☐ Average ☐ Poor

Do you think the information provided in the Report is readable?

☐ Good ☐ Fair ☐ Average ☐ Poor

What would you like to know that is not disclosed in the Report?

Your comments and suggestions on the ESG work and report preparation of the Group.